PGT-A: What It Tests, What It Cannot Tell You, and Where the Limits Lie

The short answer

PGT-A looks at the number of chromosomes in a small sample of cells taken from an embryo. It is designed to flag embryos with an extra or missing chromosome, a pattern called aneuploidy. It does not read the genetic code letter by letter, and it does not confirm that an embryo will implant, grow normally or lead to a healthy child. The HFEA’s patient information on PGT-A describes it as an assessment of chromosome number in sampled embryo cells, with limitations and the possibility of incorrect findings.

That distinction matters when you are deciding whether testing belongs in your treatment plan. PGT-A is a screening tool that adds information to a decision, not a verdict on an embryo’s future.

What the test actually examines

Human cells normally carry 46 chromosomes in 23 pairs. In aneuploidy, there is a whole extra chromosome or one missing, or a larger departure from the usual number. PGT-A is built to detect that kind of copy-number difference.

The sample usually comes from the trophectoderm, the outer cell layer of a blastocyst-stage embryo, taken by biopsy. Only a handful of cells are removed, while the rest of the embryo continues in the laboratory. The result you receive describes those sampled cells.

What PGT-A is not looking for

PGT-A does not sequence individual genes, so it is not a test for a specific inherited condition running in a family. Those questions belong to PGT-M, which addresses a known monogenic condition, and PGT-SR, which addresses chromosomal structural rearrangements. The HFEA’s overview of PGT-M and PGT-SR makes clear that these tests answer different questions and require discussion of the relevant history and test design with a treating team and genetic counsellor.

If your reason for testing is a known family condition or a known rearrangement, say so early. The test you need may not be PGT-A at all, and the laboratory preparation can differ.

Where the limitations sit

A sample is not the whole embryo

The biopsy describes a few cells. It cannot establish the cell composition of the entire embryo. This is the core reason a PGT-A report is best read as a sample-based finding rather than a whole-embryo diagnosis.

Mosaic results and their uncertain meaning

Sometimes a report shows an intermediate chromosome copy-number pattern rather than a clear normal or clear abnormal result. This is often described as mosaicism. The ASRM committee opinion on mosaic PGT-A results notes that such a result is inferred from intermediate findings in a biopsy sample, that technical factors can contribute, and that the sampled result does not establish the composition of the whole embryo. It recommends discussing the result and its uncertainty with the treating clinician and a genetic counsellor.

In practice, a mosaic report is one of the situations where patients most need a conversation rather than a search engine. What the finding means for a particular embryo, and how it should be weighed, is a clinical judgement that depends on the full report and your history.

Technical accuracy and sampling error

No laboratory test is perfect. The HFEA notes that PGT-A can produce incorrect findings, and that whether to use it should be discussed for the individual situation. A result can be affected by the biopsy itself and by the limits of the platform used. This is why the laboratory’s methods, validation and reporting language are fair questions to put to your treating team.

Biopsy carries its own small risk

Removing cells is a procedure on the embryo. The HFEA’s PGT-A questions and answers state that embryo biopsy can cause damage and prevent further development. It does not publish a figure that can be transferred to any particular clinic or laboratory, so treat any single percentage you see quoted online with caution and ask what your own clinic’s experience and consent discussion cover.

A normal result is not an outcome

An embryo reported as having the expected chromosome number may still fail to implant, and a pregnancy may still face its own uncertainties. PGT-A does not measure embryo appearance or grading, does not assess the receptivity of the uterine lining, and does not remove the influence of maternal age on an individual cycle. It also cannot promise a successful pregnancy or a healthy child, as the HFEA’s PGT-A information states.

Testing can leave you with fewer embryos to transfer

Because embryos with an abnormal result are usually not selected for transfer, testing can reduce the number available. If few embryos reach the biopsy stage, it is possible to finish a cycle with no embryo reported as suitable for transfer. That possibility belongs in the decision before testing, not after the report arrives. It is also why the number of embryos you are likely to have matters when discussing individual suitability.

Individual suitability is a clinical discussion, not a rule

There is no universal checklist that decides who should have PGT-A. The HFEA frames the decision as one to discuss for the individual situation. In a consultation, the conversation commonly touches on:

• your age at the time of treatment and what that means for chromosome risk in embryos
• ovarian reserve and how many eggs and embryos a cycle may realistically produce
• previous pregnancy losses or previous aneuploid findings
• whether a known family condition or rearrangement points to PGT-M or PGT-SR instead
• what you would do differently depending on the result, including whether you would consider transferring a mosaic embryo

These are questions for a licensed clinician who can see your records. A coordination service can help you prepare and organise the conversation, but it does not diagnose, interpret your report or recommend a treatment path.

Reading your own report

Reports vary in wording and structure. When you go through yours, it helps to identify which of these you are looking at:

Report wording	What it generally refers to	What to clarify
Euploid or normal chromosome number	No aneuploidy detected in the sampled cells	That this is a sample-based finding, not a guarantee of pregnancy
Aneuploid	A chromosome copy-number difference detected in the sample	Which chromosome, and how the clinic applies the result
Mosaic	An intermediate copy-number pattern in the sample	What the uncertainty means for this embryo and your options
No result or inconclusive	The sample did not give a usable finding	Whether a repeat biopsy is possible or advisable

Ask your clinician to walk through the specific line relating to your embryo rather than a general explanation of the test. For a closer look at how to read a report, see how to interpret PGT-A results, and for the meaning of a normal finding, what a normal PGT result does and does not mean.

Questions worth taking to your consultation

You are entitled to ask your treating clinician about your diagnosis, your options, the risks, your reports and your individual chances. A short prepared list keeps the appointment focused:

• Which test are we discussing, and why that one rather than PGT-M or PGT-SR?
• How does the laboratory validate and report its PGT-A findings, including mosaic results?
• What is the plan if no embryo is reported as suitable for transfer?
• How would a mosaic result be handled in our decision-making?
• What does the biopsy consent cover, and what is known about this laboratory’s experience?

If you are comparing hospitals or preparing for a remote consultation, a structured question list helps you compare like with like. The Thailand PGT consultation checklist is a practical starting point, and understanding PGT-A accuracy covers what to ask about laboratory methods. If age is part of your question, PGT-A for women over 40 sets out the considerations in more detail.

What this means for your planning

PGT-A can add useful information about chromosome number in an embryo, and it can also narrow your options, produce uncertain results and require careful interpretation. The sensible next step is not to decide from a web page but to arrive at your consultation with your records, your questions and a clear sense of what you would do with each kind of result. If you would like help organising records, preparing questions or coordinating a remote consultation, you can request a case review; clinical interpretation and treatment decisions stay with your treating team.

Frequently asked questions

Does a normal PGT-A result mean the embryo is healthy?

No. A normal result means no aneuploidy was detected in the sampled cells. It does not confirm that the embryo will implant, that the pregnancy will progress, or that the child will be healthy. Those outcomes depend on many factors the test does not examine.

Can PGT-A tell me whether I have a family genetic condition?

Not usually. PGT-A looks at chromosome number, not at the sequence of an individual gene. A known monogenic condition is addressed through PGT-M, and a known chromosomal structural rearrangement through PGT-SR, after discussion with your treating team and a genetic counsellor.